DMN:FRA
Diamyd Medical AB
€0.069
arrow_downward
-0.72%(-0.00050) 1D
Nov 6, 10:00:00 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€0.07
High
€0.07
Low
€0.07
Mkt. cap
148.00M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.80
52-wk low
€0.05
No. of employees
42
Open
€0.07
High
€0.07
Low
€0.07
Mkt. cap
148.00M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.80
52-wk low
€0.05
No. of employees
42
News stories
From web sources and news partners
BigGo Finance
·
2 hours ago
Global AI and Semiconductor Stocks Plunge; S&P 500 Tumbles 4.4% in a Single Day as Markets Watch Whether Three Central Banks Will Raise Rates in December
TradingView
·
15 hours ago
S&P 500 Consumer Discretionary Earnings: 89% beat EPS estimates this week
The Motley Fool
·
13 hours ago
This Dividend King Yielding 2X the S&P 500 Looks Like a Buy in November.
www.tmgm.com
·
1 day ago
United States CFTC S&P 500 NC Net Positions up to $-129.4K from previous $-134.4K
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB
CEOUlf Hannelius
Employees42
Founded1984
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitediamyd.com